Rigel Pharmaceuticals (RIGL) Competitors $21.91 +0.85 (+4.04%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$22.16 +0.25 (+1.14%) As of 08/1/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RIGL vs. DVAX, MNKD, NVAX, INVA, OPK, GERN, ZBIO, MYGN, LXRX, and EBSShould you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Dynavax Technologies (DVAX), MannKind (MNKD), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Geron (GERN), Zenas BioPharma (ZBIO), Myriad Genetics (MYGN), Lexicon Pharmaceuticals (LXRX), and Emergent Biosolutions (EBS). These companies are all part of the "biotechnology" industry. Rigel Pharmaceuticals vs. Its Competitors Dynavax Technologies MannKind Novavax Innoviva OPKO Health Geron Zenas BioPharma Myriad Genetics Lexicon Pharmaceuticals Emergent Biosolutions Rigel Pharmaceuticals (NASDAQ:RIGL) and Dynavax Technologies (NASDAQ:DVAX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability. Do institutionals & insiders have more ownership in RIGL or DVAX? 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Dynavax Technologies shares are owned by institutional investors. 9.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Dynavax Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has better valuation and earnings, RIGL or DVAX? Dynavax Technologies has higher revenue and earnings than Rigel Pharmaceuticals. Dynavax Technologies is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRigel Pharmaceuticals$179.28M2.18$17.49M$2.0710.58Dynavax Technologies$277.25M4.70$27.31M-$0.52-20.88 Is RIGL or DVAX more profitable? Rigel Pharmaceuticals has a net margin of 18.31% compared to Dynavax Technologies' net margin of -20.39%. Dynavax Technologies' return on equity of 3.59% beat Rigel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rigel Pharmaceuticals18.31% -655.26% 24.47% Dynavax Technologies -20.39%3.59%2.20% Does the media refer more to RIGL or DVAX? In the previous week, Dynavax Technologies had 2 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for Dynavax Technologies and 3 mentions for Rigel Pharmaceuticals. Dynavax Technologies' average media sentiment score of 0.89 beat Rigel Pharmaceuticals' score of 0.77 indicating that Dynavax Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dynavax Technologies 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer RIGL or DVAX? Rigel Pharmaceuticals presently has a consensus price target of $36.40, indicating a potential upside of 66.13%. Dynavax Technologies has a consensus price target of $24.00, indicating a potential upside of 120.99%. Given Dynavax Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Dynavax Technologies is more favorable than Rigel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Dynavax Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility & risk, RIGL or DVAX? Rigel Pharmaceuticals has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Dynavax Technologies has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. SummaryDynavax Technologies beats Rigel Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIGL vs. The Competition Export to ExcelMetricRigel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$376.39M$2.47B$5.47B$9.53BDividend YieldN/A1.81%4.74%4.08%P/E Ratio10.588.9728.6723.80Price / Sales2.18639.64422.2688.08Price / Cash19.52157.7635.4557.96Price / Book115.324.838.275.55Net Income$17.49M$31.62M$3.24B$259.03M7 Day Performance8.63%-5.28%-3.63%-4.56%1 Month Performance17.48%4.38%4.40%4.49%1 Year Performance125.88%-2.49%25.97%18.05% Rigel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIGLRigel Pharmaceuticals3.1714 of 5 stars$21.91+4.0%$36.40+66.1%+118.4%$376.39M$179.28M10.58160Upcoming EarningsDVAXDynavax Technologies4.1875 of 5 stars$11.29-0.6%$24.00+112.6%-0.5%$1.36B$277.25M-21.71350Positive NewsUpcoming EarningsMNKDMannKind3.2732 of 5 stars$3.96-2.5%$9.86+148.9%-32.4%$1.20B$297.60M39.60400News CoverageUpcoming EarningsNVAXNovavax4.5925 of 5 stars$7.28-2.5%$15.86+117.8%-47.8%$1.18B$682.16M2.751,990News CoverageUpcoming EarningsGap DownINVAInnoviva4.1596 of 5 stars$18.54-1.0%$40.33+117.5%-3.4%$1.16B$358.71M-18.36100OPKOPKO Health4.0323 of 5 stars$1.35-1.5%$2.75+103.7%-13.5%$1.07B$689.41M-19.282,997News CoverageEarnings ReportGap DownGERNGeron2.9955 of 5 stars$1.15-8.7%$4.61+301.0%-75.5%$732.46M$76.99M-5.48229Upcoming EarningsZBIOZenas BioPharma1.6365 of 5 stars$16.45+5.0%$36.67+122.9%N/A$688.17M$15M-4.63N/APositive NewsMYGNMyriad Genetics4.2565 of 5 stars$4.38-1.6%$14.38+228.4%-85.8%$403.75M$837.60M-3.912,700News CoverageUpcoming EarningsGap DownLXRXLexicon Pharmaceuticals2.3771 of 5 stars$1.09-0.9%$3.67+236.4%-47.0%$394.02M$31.08M-2.14140News CoverageUpcoming EarningsEBSEmergent Biosolutions4.5434 of 5 stars$6.77-5.6%$14.33+111.7%-46.6%$367.48M$1.04B-2.502,420Upcoming EarningsGap Down Related Companies and Tools Related Companies Dynavax Technologies Alternatives MannKind Alternatives Novavax Alternatives Innoviva Alternatives OPKO Health Alternatives Geron Alternatives Zenas BioPharma Alternatives Myriad Genetics Alternatives Lexicon Pharmaceuticals Alternatives Emergent Biosolutions Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RIGL) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RIGL Stock Alerts